Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Androgen Antagonists × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

pembrolizumab 4 Specimen Handling 4 Nivolumab 4 Carboplatin 4 erdafitinib 3 amivantamab 3 Magnetic Resonance Spectroscopy 3 talquetamab 2 osimertinib 2 niraparib 2 lazertinib 2 ipatasertib 2 entrectinib 2 daratumumab 2 binimetinib 2 atezolizumab 2 apalutamide 2 X-Rays 2 Sorafenib 2 Prednisone 2 Pemetrexed 2 Immunoglobulin G 2 Gemcitabine 2 Docetaxel 2 Disulfides 2 Dexamethasone 2 Dasatinib 2 Cisplatin 2 Bortezomib 2 Ado-Trastuzumab Emtansine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02489318 2026-04-13

TITAN

Aragon Pharmaceuticals, Inc.

Phase 3 Active not recruiting

1,052 enrolled 13 charts 2 FDA

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡